StockIQpro
NASDAQ:EWTX

Edgewise Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Edgewise Therapeutics, Inc. reported net income of −$167.8M in fiscal 2025. Free cash flow was −$144.1M, and the diluted share count rose 11.4%.Summary generated from Edgewise Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−34.2%
Debt / equityn/a
Free cash flow−$144.1M
FCF marginn/a
Share count change+11.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−43−72−114−159−191
Net income−43−68−100−134−168
Free cash flow−34−58−98−110−144

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations